Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
about
Structure-Guided Development of Efficacious Antifungal Agents Targeting Candida glabrata Dihydrofolate ReductaseCrystal Structures of Candida albicans Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility of Active Site Loop Residues Critical for Ligand Potency and SelectivityGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveEpidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in ItalyEpidemiology of invasive candidiasis: a persistent public health problemResults from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.Candida nivariensis isolated from an Indonesian human immunodeficiency virus-infected patient suffering from oropharyngeal candidiasis.Molecular Epidemiology and Antifungal Susceptibility of Candida glabrata in China (August 2009 to July 2014): A Multi-Center Study.Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcomeCanadian clinical practice guidelines for invasive candidiasis in adults.Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in SpainFluconazole for the management of invasive candidiasis: where do we stand after 15 years?Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingEpidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centersAnidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisAntifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy.Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infectionChanges in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing.Voriconazole: review of a broad spectrum triazole antifungal agent.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Emerging fungal diseases.Caspofungin: an overview.The changing face of fungal infections in health care settings.Echinocandin antifungals: review and update.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.Antifungal drug resistance mechanisms.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review.Invasive fungal infections in the ICU: how to approach, how to treat.Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification.Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
P2860
Q27652249-17668B11-B6AB-451E-8707-3E6DE04765C8Q27670663-BCE04514-C446-47A1-B7F5-23632AD0AEFCQ28388806-4CBE9822-D6AC-4049-B01B-DCB7496D3682Q28740362-DC428F59-70ED-4288-8465-8031827EAF3CQ29616758-66D71D06-F505-4D40-8DD5-89B9A46971B2Q30447051-BB8A42E1-EB0B-4FD8-8AD1-2F5BEDF72C7BQ33305612-14021482-D3A5-42F6-AA71-9223ABF571A9Q33715460-6EFFADB2-08F7-4311-B2E5-E2A24A161610Q33753405-1F8E860D-2179-4C98-A9FC-8CAFBC93FC4EQ33806807-97A0E16F-430A-49F6-BD99-0895EF866B4DQ33935389-B0643058-2021-447E-8373-055B7988E9BCQ34237335-05F88989-D049-4D8C-BDD0-D7E0D500298EQ34489579-432BDA76-8F0F-4B42-B659-04804230EA5EQ34490092-AF4DF874-AB78-44EB-AB27-C1F667181E1BQ34647337-FD01457D-5D3B-47C7-9127-465FCAF70C6BQ35073043-4CB08F9F-3500-414C-88B9-355EF3298CBCQ35127833-CE53F08E-E89A-4A2A-B408-7030864B30A6Q35215404-CCF7C7D3-F4B8-43C6-82A0-25373A4C4A11Q35220799-CD01B4BC-CDDA-42BE-90B5-FA33A9E4D2DAQ35912243-C32FE7A6-159E-4899-A7DF-4D8BD143A049Q35941512-A220A283-8FD6-47F9-92A4-8E8AEC2E2B6DQ35947465-D2B09C06-0E98-4CF5-941F-03AA78BC5202Q36094852-EA4BE601-65A1-4E39-B673-32B6413C0A45Q36164008-67B62C68-DFBA-42C6-9AC7-108BB311AC8FQ36176371-4E817A7E-A1FB-4590-9AAC-325B6E62DC4FQ36199785-6EDF4E93-7DDC-4B3A-B614-68E35C0AC7E6Q36278031-4908CDCB-1B6D-471C-A916-BA14CCCA954BQ36289060-DBAAA5E3-7010-448C-8414-F027D0E1587AQ36441524-1BD1373D-8084-44F7-AE3D-ADD7B225EF5DQ36491819-F699C581-A00B-4CAE-AC6A-6595A3246409Q37048679-6C03CFFA-8373-484B-9D2C-96499B5CC386Q37055215-B9C70D4D-944A-4A71-B073-7AAFA7639969Q37374850-9BB537F8-5F50-42BE-A922-59BCB859E2ECQ37443139-AB553717-ACF6-4044-B28B-C3D726551C95Q37463223-8E402904-1BF1-4B78-AE92-8E053A809807Q37608276-0296F350-2172-4C42-B241-E5108E0A3126Q38085729-E2C3AEBF-2FE5-450A-970F-29E9AAB1251FQ38180287-DDFEEBAD-79FC-47F8-84A0-61D66C6B790EQ38609418-35E380F8-E8B8-4D3F-B510-122C561E6687Q39445046-692EA7AE-CC4D-435B-9DE2-B6D2D1FD344E
P2860
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Geographic variation in the su ...... am conducted in 2001 and 2002.
@ast
Geographic variation in the su ...... am conducted in 2001 and 2002.
@en
type
label
Geographic variation in the su ...... am conducted in 2001 and 2002.
@ast
Geographic variation in the su ...... am conducted in 2001 and 2002.
@en
prefLabel
Geographic variation in the su ...... am conducted in 2001 and 2002.
@ast
Geographic variation in the su ...... am conducted in 2001 and 2002.
@en
P2093
P2860
P1476
Geographic variation in the su ...... am conducted in 2001 and 2002.
@en
P2093
D J Diekema
M A Pfaller
R J Hollis
S A Messer
S Tendolkar
P2860
P304
P356
10.1128/JCM.42.7.3142-3146.2004
P407
P577
2004-07-01T00:00:00Z